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Abstract 16 
In this work, a simple, cost-effective, and label-free biosensor was constructed for 17 
methamphetamine (METH) detection. The biosensor consists of a 18 
G-quadruplex-hemin DNAzyme molecular beacon (DNAzyme MB), a METH 19 
aptamer, and a colorimetric substrate. The DNAzyme MB loses peroxidase activity 20 
when it hybridizes with the METH aptamer. In the presence of METH, DNAzyme 21 
MB dissociates from the inactive hybrid due to preferable hybridization of METH 22 
with the aptamer. This process recovers the activity of DNAzyme MB, which 23 
catalyzes a reaction with the colorimetric substrate to yield measurable signals. Under 24 
optimized conditions, a detection limit as low as 0.5 nM (74.6 ng L-1) was achieved. 25 
Common illicit drugs were found to have little interference on detection of METH. 26 
Recoveries of METH spiked in urines of addicts were greater than 85%. Good 27 
agreement was observed between METH concentrations in urines determined by the 28 
sensor and by liquid chromatography-tandem mass spectrometer. These results 29 
indicate that the G-quadruplex-hemin DNAzyme MB probe holds promise to detect 30 
METH not only in biological samples, but also in environmental matrices.  31 
 32 
Introduction 33 
The abuse of illicit drugs is a worldwide problem that has severe societal 34 
consequences, such as loss of lives and health of abusers, increased treatment costs, 35 
and higher incidence of crimes1-3. United Nations Office of Drugs and Crimes has 36 
recently estimated that a total of 246 million people, corresponding to 5 % of the 37 
world population aged between 15 and 64, had used illicit drugs at least once in 2013 38 
4. Among the illicit drugs, methamphetamine (METH) is second only to marijuana as 39 
the most widely abused illicit drug on the world5-7. METH abuse has increased 40 
dramatically in the recent years in certain regions of the world. For example, 41 
crystalline METH seizure has increased from a little over 7t in 2010 to 14t in 2013 in 42 
East and Southeast Asia 4. To monitor and control METH abuse, samples of different 43 
matrices (e.g., urine, blood, and wastewater) need to be analyzed.  44 
Traditional methods for the quantitative METH analysis include gas 45 
chromatography-mass spectrometry8, 9, high performance liquid chromatography- 46 
mass spectrometry2, 3, ion mobility spectrometry10, imaging mass spectrometry11, 47 
surface enhanced Raman spectroscopy and microfluidics12, 13, etc. Although highly 48 
sensitive and selective, these techniques require expensive instruments and tedious 49 
sample pretreatment in laboratory, preventing its use for onsite detection. Thus, there 50 
is a need to develop simple, cost-effective tools that are able to accurately and rapidly 51 
monitor low levels of METH at the site of sample collection. 52 
The limitations of conventional analytical tools maybe overcome by biosensors. A 53 
biosensor is a small device with a biological receptor that generates a signal 54 
(electrochemical, optical, nanomechanical, mass sensitive, etc.) in the presence of an 55 
analyte. Biosensors have great promise for on-site detection of analytes in body fluids 56 
and environment samples, as it have the advantages of miniaturization and being 57 
potentially portable and capable of measuring complex matrices with minimal sample 58 
preparation14-16. In the past few decades, biosensors have been developed to measure 59 
numerous analytes in various matrices, such as heavy metals 17, small molecule18, 19, 60 
targeted DNA14, 20, peptides21, enzyme22, protein21, biomarkers14, 15 and even 61 
bacteria23, 24. 62 
Among biosensors, DNAzymes based sensors known as catalytic beacons have 63 
been extensively investigated due to its high specificity and sensitivity25-29. 64 
DNAzymes are catalytically active DNA molecules that are able to catalyze chemical 65 
reactions25, 26. Compared to protein enzymes, DNAzymes are chemically more stable, 66 
inexpensive, simple to synthesize and easy to modify28, 29. One important and 67 
increasingly popular type of DNAzymes is the G-quadruplex-hemin complexes that 68 
have peroxidase activity26, 29-34. This class of DNAzyme has been used to detect 69 
targets from proteins and DNAs29, 30, to small molecules and metal ions30-32. However, 70 
to our knowledge, no attempt has been reported in the literature to detect METH using 71 
DNAzyme-based sensors.  72 
In this work, we developed a colorimetric biosensor for METH detection that was 73 
based on the G-quadruplex-hemin DNAzyme MB, a METH aptamer, and a 74 
colorimetric substrate. The sensor was optimized by varying the number of base pair 75 
of the MB. Selectivity of the sensor was examined using 15 commonly illicit drugs 76 
other than METH. The optimized sensor was used to detect METH in urine specimens 77 
of drug addicts and compared to measurement by liquid chromatography –tandem 78 
mass spectroscopy. The highly sensitive and specific sensor reported here has the 79 
potential for onsite detection of METH in biological and environmental samples.  80 
 81 
Materials and Methods 82 
Biosensor construction and optimization 83 
The biosensor consisted of a DNAzyme MB, hemin, a METH aptamer, and a 84 
colorimetric substrate. The DNAzyme MB is expected to bind METH aptamer 85 
through hybridization to form a catalytically inactive double strands DNA (dsDNA).  86 
In the presence of METH, would dissociate from the inactive dsDNA due to 87 
preferable binding between METH and the aptamer. The dissociated DNAzyme MB 88 
is expected to bind with hemin to form the G-quadruplex-hemin, which could catalyze 89 
a colorimetric reaction of a substrate to generate a signal that can be measured by a 90 
spectrometer. The designed mechanism of the biosensor is illustrated in Figure 1.  91 
To confirm the effectiveness of the designed mechanism, a DNAzyme MB with a 92 
sequence of 5’-AGGGACGGGTGCCAACGTTCACCCTGAGACCATCCGACCCA 93 
ATAAACCGTGGAGGGT-3’ (MB1) and a METH aptamer with a sequence 5′- 94 
ACGGTTGCAAGTGGGACTCTGGTAGGCTGGGTAATTTGG-3′ were tested.  95 
Both the MB and the aptamer were synthesized and purified using HPLC by Sangon 96 
Biotech Co. Ltd. (Shanghai, China). The colorimetric substrate chosen in this work is 97 
2, 2’-azinobis (3-ethylbenzothiozoline)-6- sulfonic acid (ABTS), which is obtained 98 
from J&K Scientific (Beijing, China). Both MB1 and the aptamer were dissolved in 99 
HEPES buffer (25 mM HEPES, 20 mM KCl, 200 mM NaCl, pH 7.40) to a 100 
concentration of 10 μM.  101 
The MB1 and aptamer solutions were first denatured for 5 min at 90°C and cooled 102 
down slowly to the room temperature. The cooled MB1 and aptamer solutions (20 µL 103 
each) were mixed in 70 µL HEPES buffer and incubated at 37°C for 30 min. Then 40 104 
µL of 10 µM METH and 10 µL of 5 µM hemin (Alfa Aesar Chemicals Co. Ltd., 105 
Shanghai, China) were added to yield a total volume of 160 µL. After the mixture was 106 
incubated at 37°C for 1 h, 20 µL 7.2 mM ABTS and 20 µL H2O2 (15‰, v/v) were 107 
added. UV-Vis spectra measurement was performed at a wavelength of 415 nm, after 108 
the mixture was vortexed to react for 10 min at room temperature. 109 
Control experiments were performed with following combinations: hemin + 110 
ABTS+ H2O2; MB1 + hemin + ABTS + H2O2; MB1 + aptamer + hemin + ABTS + 111 
H2O2. In these experiments, each component was added at the same volumes and 112 
concentrations as in the presence of METH. The missing components were replaced 113 
by the HEPES buffer to maintain a constant total volume (200 µL). 114 
The biosensor was optimized using two DNAzyme MBs of different lengths, 115 
following the same procedure mentioned above. The sequences of the DNAzyme 116 
MBs were 5’-AGGGACGGGTGCCAACGTTCACCCTGAGACCATCCGACCCAA 117 
TAAACCGTGGAGGGT-3’ (MB 2), and 5’- AGGGACGGGCACCCTGAG 118 
ACCATCCGACGTGGAGGGT-3’ (MB 3).  119 
Detection of MEHT in aqueous solutions 120 
MB 3 was used in the biosensor for further experiments. The sensitivity and 121 
linearity of the biosensor to detect METH were examined with the procedure 122 
mentioned above, at following final METH concentrations: 0, 0.50, 1.00, 2.00, 4.00, 123 
6.00, 8.00, 10.00, 20.00, 40.00, 60.00, 80.00, 100.00, 200.00, 500.00, 1000 nM.  124 
Possible interference by other illicit drugs 125 
Selectivity of the biosensor was examined using 15 common illicit drugs and 126 
metabolites, namely, ketamine (KET), norketamine (NK), morphine (MOR), 127 
methadone (MTD), cocaine (COC), mephedrone (MEP), cathinone (CAT), 128 
methcathinone (MCAT), 3-trifluoromethyphenylpiperazine (BZP), 129 
1-(3-trifluoromethylphenyl) piperazine (TFMPP), 3,4-Meth-ylenedioxypyrovalerone 130 
(MDPV), MDA, MDMA, EDDP, and mCPP. These drugs and metabolites were all 131 
purchased from Cerilliant (Round Rock, TX, USA). The experiment procedure was 132 
same as above, except that METH was replaced by other illicit drugs or metabolites. A 133 
much higher concentration (1 mg L-1) was used for other drugs and metabolites, 134 
where as a METH concentration of 15 ng L-1 was used as control.  135 
Analysis of urine samples 136 
To test the feasibility to detect METH in real samples, METH concentrations in 137 
urines were determined using the biosensor. Five urine samples of the METH addicts 138 
were provided by local drug police in Shandong province. The urine samples were 139 
filtered using 0.22 µm syringe filters. An aliquot of 20µL of each samples were used 140 
for detection, following the procedure mentioned above. The measured concentrations 141 
were compared with those determined using high performance liquid 142 
chromatography-tandem mass spectrometer (HPLC-MS/MS). The HPLC-MS/MS 143 
used a UFLCXR-LC system (Shimadzu, Japan) with a Phenomenex Gemini C18 144 
column (100 mm  2 mm, 3 µm) and an ABI 4000 triple quadrupole mass 145 
spectrometer (AB SCIEX, USA).  To examine the recovery of METH, one of the 146 
urine samples was spiked with three concentrations (50, 100, and 200 ng L-1). The 147 
METH concentrations in spiked samples were then determined using the biosensor.  148 
 149 
Results and discussion 150 
Confirmation of biosensor mechanism 151 
In the control experiment using ABTS, hemin, and H2O2 only, an absolute 152 
absorbance intensity of 0.35 was observed. When MB1 was added to the system, the 153 
absorbance intensity increased dramatically (Figure 1, MB). This is because of the 154 
formation of the G-quadruplex-hemin complex that has peroxidase activity and that 155 
catalyzes ABTS oxidation by H2O2 to produce ABTS
·+. The formation of ABTS·+ lead 156 
to an increase in absorbance signal at 415 nm31, 33, 34. When METH aptamer was 157 
further added to the system, the absorbance was drastically reduced (Figure 1, 158 
MB+Apt). The signal was only slightly higher than that of the system of ABTS, 159 
hemin, and H2O2 only. The decrease in absorbance in the presence of METH aptamer 160 
is due to binding between MB1 and METH aptamer following the base pair matching 161 
principle to form dsDNA. The dsDNA is catalytically inactive, preventing the 162 
formation of G-quadruplex-hemin complex and conversion of ABTS into ABTS·+. 163 
Finally, when METH was added to the system, absorbance was recovered to about 164 
82% of the intensity observed in presence of MB1 and absence of METH aptamer 165 
(Figure 1, MB+Apt+METH). The recovery in absorbance confirms the preferable 166 
binding of METH and the aptamer, which leads to dissociation of dsDNA, formation 167 
of G-quadruplex-hemin complex, and conversion of ABTS into ABTS·+. These results 168 
indicate that designed mechanism is effective to detect METH.   169 
Optimal biosensor 170 
The length of DNAzyme MB, i.e. the number of base pairs, has a great influence on 171 
its catalytic activity as a result of its effects on the formation of G-quadruplex 172 
structure and its decisive role in the stability of dsDNA formed with the METH 173 
aptamer. Excessive base pairs would hinder the dissociation of METH aptamer from 174 
the dsDNA in the presence of METH, whereas insufficient base pairs could prevent 175 
the DNAzyme MB from forming the G-quadruplex-hemin complex. All the three 176 
DNAzyme MBs could increase the absorbance in the absence of METH and METH 177 
aptamer (Figure 2). MB 2 had the maximal signal intensity, which means the length of 178 
MB 2 was optimal for formation of the G-quadruplex structure. Yet the dissociation of 179 
METH aptamer from the dsDNA must be considered as well. In the presence of 180 
METH aptamer and METH, MB 3 showed the greatest signal intensity (Figure 3), 181 
indicating that fewer base pairs could facilitate dissociation of METH aptamer and 182 
formation of METH-aptamer complex. Thus MB 3 was chosen to construct the 183 
optimal biosensor which was used for all further experiments.  184 
Sensitivity and linearity of METH detection 185 
As shown in Figure 4A, the signal intensity was dependent on the concentration of 186 
METH over a range of 0-1000 nM when the concentrations of MB3 and METH 187 
aptamer were set at 1 M. The limit of detection (LOD) of the biosensor was 188 
calculated to be 0.5 nM (3 times standard deviation rule).The insert of Fig. 4A shows 189 
that the signal intensity at 415 nm displayed an excellent linearity with the METH 190 
concentration ranging from 8 nM to 500 nM (R2=0.991). In addition, the logarithmic 191 
concentration also exhibited a linear relationship with the corresponding absorbance 192 
signal intensity (R2= 0.983) in a METH concentration range from 0.5 nM to 200 nM 193 
(figure not shown). Furthermore, compared with the blank (METH concentration = 0), 194 
color changes were visible even with the bare eyes at METH concentrations of 0.50 195 
nM and above (Figure 4B).  196 
The detection limit of the biosensor developed here was at least 2 orders of 197 
magnitude lower than the previous sensors. For example, Shi et al. developed a 198 
biosensor based on METH aptamer and gold nanoparticles and reported a detection 199 
limit of 0.82 μM7. Oghli et al. developed an electrochemical sensor that had a 200 
detection limit of 50 nM35. Furthermore, the detection limit of this assay for METH is 201 
much lower than 1000 ng mL-1 (6.7 μM), the threshold of positive methamphetamine 202 
detection in urine samples recommended by the National Institute on Drug Abuse of 203 
United States36. Furthermore, the proposed biosensor for METH had higher sensitivity 204 
than the limited biosensors and chemical sensors reported in the literature.  205 
Selectivity of the biosensor 206 
In the presence of the 15 illicit drugs or metabolites (at a concentration of 1 mg L-1) 207 
other than METH, absorbance signals greater than blank (less than 0.2) were observed 208 
(Figure 5). However, these signals were much lower than that in the presence of 209 
METH, despite the fact that METH concentration (15 μg L-1) was much lower 210 
Furthermore, the enhancement in absorbance signals (relative to the blank) was not 211 
statistically significant among other drugs, indicating that interference of these drugs 212 
to METH detection was not specific. These results demonstrate that binding affinity 213 
of METH to METH-aptamer were much stronger than that to all other illicit drugs, 214 
rendering the biosensor with high specificity toward METH.  215 
Detection of METH in urine samples 216 
In order to further investigate the potential application of the newly-designed sensor 217 
in the practical samples, the assay was employed to detect METH in urine samples. 218 
Average recovery of METH in spiked urine sampled ranged from 85.1 and 89.1% 219 
(Table 1). The METH concentrations analyzed using the our biosensor ranged from 220 
23.2 to 587 ng mL-1 (Figure 6) METH concentrations derived from HPLC-MS/MS 221 
fell within the same range. For the particular urine samples, deviations of 222 
biosensor-derived concentrations from HPLC-MS/MS-derived concentrations were all 223 
less than 7.9 %. These results demonstrate the accuracy and validity of the biosensor 224 
to detect METH in real samples.  225 
 226 
Conclusion 227 
A simple, cost-effective, and label-free biosensor based on the G-quadruplex-hemin 228 
DNAzyme MB was constructed for METH detection. The biosensor had a detection 229 
limit of 0.5 nM and a linear range was 8-500 nM. Other common illicit drugs had 230 
little interference on the detection of METH. Recoveries of METH in the spiked urine 231 
samples were more than 85%. The concentrations of METH in urine samples derived 232 
from the biosensor agreed well with the concentration derived from HPLC-MS/MS. 233 
The high sensitivity and specificity indicates that the biosensor could be a promising 234 
tool for onsite detection of METH. The DNAzyme MB probe may offer a new 235 
approach for sensitive and selective detection of a wide spectrum of analytes by 236 
changing some bases of MBs and choosing different aptamers. 237 
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Tab.1. Recovery of METH in urines at three spiked METH concentration (50.0, 306 
100.0 and 200.0 g L-1), respectively. 307 
 308 
 309 
 310 
 311 
Spiked 
concentration 
(g L-1) 
The measured concentration  
of  METH (g L-1) 
Rate of  
standard recovery 
(%)  
 1 2 3 Average 1 2 3 Average 
0 57.7 63.5 58.3 59.8  - - - - 
50 103.2 110.7 99.2 104.4  91.0  94.4  81.8  89.1  
100 146.3 151.2 139.8 145.8  88.6  87.7  81.5  86.0  
200 235.6 227.6 226.9 230.0  89.0  82.1  84.3  85.1  
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Scheme 1. Schematic representation of colorimetric detection of METH. 
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Figure 1. Absorbance at 415 nm from the ABTS oxidation for the analysis of METH. 
An amount of 1 µM DNAzyme MB1/METH aptamer was employed. MB: 1 µM 
DNAzyme MB1 +250 nM hemin+ABTS/H2O2; MB+Apt: 1 µM DNAzyme MB 
1/METH aptamer +250 nM hemin +ABTS/H2O2; MB+Apt+METH: 1 µM DNAzyme 
MB1/METH aptamer+250 nM hemin+2 µM METH+ABTS/H2O2; None: 250 nM 
hemin +ABTS/H2O2. The signal (△A) is expressed as the relative absorbance with 
respect to the blank and error bars represent three replicate measurements (same for 
below).  
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Figure 2. Effect of DNAzyme MB length on the absorbance at 415 nm for the analysis 
in the absence of METH. The reaction systems contain 1 μM DNAzyme MB with 
different lengths and 1 μM METH aptamer without METH.  
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Figure 3. Effect of DNAzyme MB length on the absorption at 415 nm for the analysis 
in the presence of METH. The reaction systems contain 1 μM DNAzyme MB with 
different lengths and 1 μM METH aptamer in the presence of METH.  
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Figure 4. (A) Absorbance at 415 nm from the ABTS oxidation for the analysis of 
METH at concentrations ranging from 0 to 1000 nM (0, 0.5, 1.0, 2.0, 4.00, 6.0, 8.0, 
10.0, 20.0, 40.0, 60.0, 80.0, 100.0, 200.0, 500.0, 1000.0 nM). The inset shows the 
linear range. (B) Color changes of the the G-quadruplex-hemin DNAzyme MB probe 
in the presence of METH. The METH concentrations in tubes from left to right were: 
0 (blank), 0.5 nM, 1.0 nM, 5.0 nM, 10.0 nM, 50.0 nM, 100.0 nM, 200.0 nM, 500.0 
nM, and 1000.0 nM. 
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Figure 5. Selectivity of the G-quadruplex-hemin DNAzyme MB probe for METH. 
The METH concentration was 15 g L-1 (100 nM), while the concentration of other 
illicit drugs was 1000 g L-1. From left to right: METH, KET, NK, MOR, MTD, COC, 
MEP, MDMA, CAT, MCAT, BZP, TFMPP, MDPV, MDA, EDDP, m-CPP, and blank. 
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Figure 6. METH concentrations in human urine samples measured by the 
G-quadruplex-hemin DNAzyme MB probe (red) and by LC-MS/MS (black).  
 
